What has been the number one challenge that has impacted you over the past year?

Due to the recent global restructuring of the company, I have been forced to be much more strategic and effective in decision-making and prioritizing efforts. Additionally, various economic, social and health crises resulting from the pandemic have proven to be an interesting challenge that we have managed to overcome with the aim of helping health systems meet the needs of their patients.

In which ways have you attempted to bring the legal department closer to your business colleagues?

We decided to make the legal department one more member of the business – by seeing the business as a client and becoming its allies. This was achieved by understanding the business, designing strategies together, anticipating scenarios and taking intelligent risks. This tactic represents a greater effort that has undoubtedly paid off; today, the legal department is seen as a business partner that ensures goals are efficiently met and not only as a barrier that prevents the business from implementing new ideas.

What are some of the most significant cases and transactions you have been involved in recently?

We have been involved in various successful negotiations with Ministries of Health, Social Security Institutes, and other actors in the region’s health system, generating access to innovative therapies that benefit patients.

Additionally, we have successfully created distribution and marketing agreements with leading companies in the region for various products from our portfolio, which allow us to streamline our efforts.

Finally, we have overseen the security of the intellectual property rights of several of our products in various countries of the region, allowing us to value the importance of innovation, considering the effort research and development of new molecules represents.